Enzyme induction and histopathology elucidate aryl hydrocarbon receptor-mediated versus non-aryl hydrocarbon receptor-mediated effects of Aroclor 1268 in American mink (Neovison vison)

2016 ◽  
Vol 35 (3) ◽  
pp. 619-634 ◽  
Author(s):  
William R. Folland ◽  
John L. Newsted ◽  
Scott D. Fitzgerald ◽  
Phyllis C. Fuchsman ◽  
Patrick W. Bradley ◽  
...  
2020 ◽  
Vol 21 (21) ◽  
pp. 7931
Author(s):  
Nada H. Eisa ◽  
Sakamuri V. Reddy ◽  
Ahmed M. Elmansi ◽  
Galina Kondrikova ◽  
Dmitry Kondrikov ◽  
...  

There is increasing evidence of the involvement of the tryptophan metabolite kynurenine (KYN) in disrupting osteogenesis and contributing to aging-related bone loss. Here, we show that KYN has an effect on bone resorption by increasing osteoclastogenesis. We have previously reported that in vivo treatment with KYN significantly increased osteoclast number lining bone surfaces. Here, we report the direct effect of KYN on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclastogenesis in Raw 264.7 macrophage cells, and we propose a potential mechanism for these KYN-mediated effects. We show that KYN/RANKL treatment results in enhancement of RANKL-induced osteoclast differentiation. KYN drives upregulation and activation of the key osteoclast transcription factors, c-fos and NFATc1 resulting in an increase in the number of multinucleated TRAP+ osteoclasts, and in hydroxyapatite bone resorptive activity. Mechanistically, the KYN receptor, aryl hydrocarbon receptor (AhR), plays an important role in the induction of osteoclastogenesis. We show that blocking AhR signaling using an AhR antagonist, or AhR siRNA, downregulates the KYN/RANKL-mediated increase in c-fos and NFATc1 and inhibits the formation of multinucleated TRAP + osteoclasts. Altogether, this work highlights that the novelty of the KYN and AhR pathways might have a potential role in helping to regulate osteoclast function with age and supports pursuing additional research to determine if they are potential therapeutic targets for the prevention or treatment of osteoporosis.


2009 ◽  
Vol 29 (8) ◽  
pp. 689-694 ◽  
Author(s):  
Hisaka Kurita ◽  
Wataru Yoshioka ◽  
Noriko Nishimura ◽  
Naoto Kubota ◽  
Takashi Kadowaki ◽  
...  

2019 ◽  
Vol 54 (3) ◽  
pp. 1770-1781 ◽  
Author(s):  
Ji-Hee Hwang ◽  
Kurunthachalam Kannan ◽  
Thomas J. Evans ◽  
Hisato Iwata ◽  
Eun-Young Kim

1998 ◽  
Vol 11 (12) ◽  
pp. 1447-1452 ◽  
Author(s):  
Roland Frötschl ◽  
Lubomir Chichmanov ◽  
Ullrich Kleeberg ◽  
Alfred G. Hildebrandt ◽  
Ivar Roots ◽  
...  

2007 ◽  
Vol 20 (9) ◽  
pp. 1237-1241 ◽  
Author(s):  
Takeshi Ohura ◽  
Maki Morita ◽  
Masakazu Makino ◽  
Takashi Amagai ◽  
Kayoko Shimoi

Blood ◽  
2008 ◽  
Vol 112 (4) ◽  
pp. 1214-1222 ◽  
Author(s):  
Ehud Hauben ◽  
Silvia Gregori ◽  
Elena Draghici ◽  
Barbara Migliavacca ◽  
Stefano Olivieri ◽  
...  

Abstract VAF347 is a low-molecular-weight compound, which activates the aryl hydrocarbon receptor (AhR). Herein, we report that oral administration of a water-soluble derivative of VAF347 (VAG539) promotes long-term graft acceptance and active tolerance in Balb/c mice that receive a transplant of MHC-mismatched pancreatic islet allografts. In vivo VAG539 treatment results in increased frequency of splenic CD4+ T cells expressing CD25 and Foxp3, markers associated with regulatory T (Tr) cells, and in vitro VAF347 treatment of splenic CD4+ T cells improved CD4+CD25+Foxp3+ T-cell survival. Interestingly, transfer of CD11c+ dendritic cells (DCs), but not of CD4+ T or CD19+ B cells, from VAG539-treated long-term tolerant hosts into mice that recently underwent transplantation resulted in donor (C57Bl/6)–specific graft acceptance and in a significantly higher frequency of splenic CD4+CD25+Foxp3+ Tr cells. Furthermore, the transfer of CD4+CD25+ T cells from these mice into mice that recently underwent transplantation promoted graft acceptance. Similarly, cell therapy with in vitro VAF347-treated bone marrow–derived mature DCs prevented islet graft rejection, and reduced OVA-specific T-cell responses in OVA-immunized mice. Collectively, our data indicate that AhR activation induces islet allograft–specific tolerance through direct as well as DC-mediated effects on Tr-cell survival and function.


Sign in / Sign up

Export Citation Format

Share Document